PF-06804103

· Pfizer

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PF-06804103, covering 2024-09-03 to 2024-09-03. Get the full timeline:

Most recent: Clinical Trial Update: PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors [Phase 1]